Physician profile
David Mark Pizzano
NPI 1013910561
$2,605.60
in general payments reported to CMS, 2019-2025
23 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $310 · 2021: $297 · 2022: $356 · 2023: $833 · 2024: $403 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $702.89 | 2022-2025 | Citrefix, Augment Injectable, 7 X 23mm Citrelock Implant |
| Horizon Therapeutics Plc | $635.04 | 2019-2023 | Krystexxa |
| Treace Medical Concepts, INC. | $488.52 | 2020-2025 | |
| Amgen INC. | $120.29 | 2024 | Krystexxa |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.33 | 2023-2025 | Jublia |
| Smith+Nephew, INC. | $77.36 | 2022-2025 | Collagenase Santyl, Grafix Pl |
| Paragon 28, INC. | $72.06 | 2022-2024 | Phantom Intramedullary Nail |
| Bioventus LLC | $68.06 | 2019-2021 | |
| Orthofix Medical, INC. | $43.42 | 2025 | Physio-Stim |
| Averitas Pharma INC. | $39.91 | 2023 | Qutenza |
| Merck Sharp & Dohme LLC | $37.37 | 2019 | |
| Sebela Pharmaceuticals INC. | $29.41 | 2019-2020 | |
| Integra Lifesciences Corporation | $26.12 | 2019 | |
| Organogenesis INC. | $22.99 | 2024 | |
| Heron Therapeutics, INC. | $22.89 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $19.65 | 2021 | |
| Dynasplint Systems INC. | $18.53 | 2025 | Dynasplint |
| Seapearl East, INC | $17.27 | 2021 | |
| Grt US Holding, INC. | $17.26 | 2021 | |
| Nabriva Therapeutics, Plc | $14.00 | 2020 | |
| Zyla Life Sciences, INC. | $13.16 | 2020 | |
| Melinta Therapeutics, LLC | $12.68 | 2019 | |
| Arthrosurface Incorporated | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pizzano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.